DENVER--(BUSINESS WIRE)--Ceragenix Pharmaceuticals, Inc. (OTCB:CGXP), a biopharmaceutical company focused on infectious disease and dermatology today announced that recent in vitro testing has shown that its Cerashield™ antimicrobial coating applied to endotracheal tube segments was able to completely prevent bacterial adhesion and biofilm formation in a 14 day continuous challenge with 10E6 of Pseudomonas aeruginosa.
